公开(公告)号：US20150232956A1

公开(公告)日：2015-08-20

申请号：US14262266

申请日：2014-04-25

Applicant: I-SHOU UNIVERSITY

Inventor： YUN-JU CHEN ,  WEI-CHIEN HUANG ,  JHEN-YU CHEN ,  PEI-HSUAN CHIEN ,  WEN-SHU CHEN

IPC: C12Q1/70 ,  C12Q1/68

CPC classification number: C12Q1/706 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: The invention discloses a method for evaluating therapeutic effects of lapatinib on liver cancer comprising: obtaining a liver cancer biopsy from a patient; determining level of a biomarker in the liver cancer biopsy obtained from the patient ex vivo; comparing the determined level of the biomarker in the liver cancer biopsy obtained from the patient to a reference level of the biomarker; and predicting therapeutic effect of lapatinib on liver cancer according to the comparison between the determined level and the reference level of the biomarker; wherein the reference level of the biomarker is level of the biomarker in a liver biopsy obtained from a normal, non-cancerous subject; wherein the biomarker is HBx or ErbB3.

Abstract translation: 本发明公开了一种评估拉帕替尼对肝癌治疗效果的方法，包括：从患者获得肝癌活检; 确定从患者体内获得的肝癌活检中生物标志物的水平; 将从患者获得的肝癌活检中的生物标志物的确定水平与生物标志物的参考水平进行比较; 并根据确定的水平与生物标志物的参考水平之间的比较预测拉帕替尼对肝癌的治疗效果; 其中所述生物标志物的参考水平是从正常非癌症受试者获得的肝活组织检查中的生物标志物的水平; 其中所述生物标志物是HBx或ErbB3。